TFAP is a cell-permeable pyridinyl-benzamide compound that acts as a COX-1-selective inhibitor by targeting the enzyme's active site. TFAP exhibits analgesic properties in mice and rats in vivo without long-term cytotoxic effects. Unlike COX-2-inhibiting analgesics such as aspirin, TFAP is shown not to cause gastric damage in rats in vivo.